Viral Vector Process Development & Manufacturing Summit
Create Qualitative, Accessible Treatments for Patients
Following Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities, and BMS’s viral vector facility coming online, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies.
With the FDA’s fast-evolving quality assessment and lack of standard guidance, and the continued challenge of viral vector recovery yield and purity, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations.
In collaboration with Sarepta, Ultragenyx, Affinia Therapeutics, and UCB, we will unite 130+ pioneering viral vector up- and downstream process engineers, MSAT, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up, tech transfer, and speed-to-clinic. Returning to Boston in February, we are proud to expand the program into 2 tracks of content as the only industry-led, end-to-end summit to align with your needs:
- Downstream process intensification, including purification, to improve recovery and yield
- Purity assessment to uphold GMP and product quality assessment
- Deep dive into upstream process development and cell line in relation to your viral vectors, and assess platforming strategy
- Rapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs
- Meet and evaluate solution providers and viral vector CDMOs, including Lonza, Chromatan, Teknova, and Genezen, to forge long-term relationships, ensuring tech transfer readiness
It’s worth clearing 3 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing!
To know more visit: https://ter.li/fvlk3e